Does the timing of comorbidity affect colorectal cancer survival? A population based study

Postgraduate Medical Journal

Volumn 86, Issue 1012, 2010, Pages 73-78

  Shack, Lorraine G ^a,b   Rachet, Bernard ^a   Williams, Evelyn M I ^c   Northover, John M A ^d   Coleman, Michel P ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b ALBERTA HEALTH SERVICES   (Canada)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d ST MARK S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; OBESITY; POPULATION RESEARCH; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; COMORBIDITY; DATA COLLECTION; ENGLAND; FEASIBILITY STUDIES; HUMANS; MIDDLE AGED; PREVALENCE; YOUNG ADULT;

EID: 76649137636     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/pgmj.2009.084566     Document Type: Article

References (37)

1. De Marco MF, Janssen-Heijnen MLG, van der Heijden LH, et al. Comorbidity and colorectal cancer according to subsite and stage: a population-based study. Eur J Cancer 2000;36:95-9.
2. Gross CP, McAvay GJ, Krumholz HM, et al. The effect of age and chronic illness on life expectancy after a diagnosis of colorectal cancer: implications for screening. Ann Intern Med 2006;145:646-54.
3. Stukenborg GJ, Wagner DP, Connors AF. Comparison of the performance of two comorbidity measures, with and without information from prior hospitalizations. Med Care 2001;39:727-39.
4. Stockton DL. Cancer survival in Scotland: understanding variations. London: London School of Hygiene and Tropical Medicine, 2001.
5. Charlson ME, Pompei P, Ales K. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
6. Southern DA, Quan H, Ghali WA. Comparison of the Elixhauser and Charlson/Deyo methods of comorbidity measurement in administrative data. Med Care 2004;42:355-60.
7. Ghali WA, Hall RE, Rosen AK. Searching for an improved clinical comorbidity index for use with ICD-9-CM administrative data. J Clin Epidemiol 1996;49:273-78.
8. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19.
9. American society of anaesthesiologists. ASA physical status classification system. American Society of Anaesthesiologists 2008. http://www.asahq.org/clinical/ physicalstatus (accessed 7 March 2008).
10. Sundararajan V, Henderson T, Perry C, et al. New ICD-10 version of Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol 2004;57:1288-94.
11. Elixhauser A, Steiner C, Harris DR, et al. Comorbidity measures for use with administrative data. Med Care 1998;36:8-27.
12. Zhang JX, Iwashyna TJ, Christakis NA. The performance of different look back periods and sources of information for Charlson comorbidity adjustment in Medicare claims. Med Care 1999;37:1128-39.
13. Preen DB, Holman CD, Spilsbury K, et al. Length of comorbidity lookback period affected regression model performance of administrative health data. J Clin Epidemiol 2006;59:940-6.
14. Munro AJ, Bentley AHM. Deprivation, comorbidity and survival in a cohort of patients with colorectal cancer. Eur J Cancer Care(Engl) 2004;13:262.
15. Lemmens VE, Janssen-Heijnen ML, Verheij CD, et al. Repelaer va Driel OJ, Coebergh JW. Co-morbidity leads to altered treatment and worse survival of elderly patients with colorectal cancer. Br J Surg 2005;92:615-23.
16. Gross CP, Guo Z, McAvay GJ, et al. Multimorbidity and survival in older persons with colorectal cancer. J Am Geriatr Soc 2006;54:1898-904.
17. NHS Connecting for Health. OPCS Classification of Interventions and Procedures Version 4.3. London: The Stationery Office, 2006.
18. Moons KG, Harell FE, Steyerberg EW. Should scoring rules be based on odds ratios or regression coefficients? J Clin Epidemiol 2008;55:1054-155.
19. Berkson J, Gage RP. Calculation of survival rates for cancer. Proc Staff Meet Mayo Clinic 1950;25:270-86.
20. Office for National Statistics. National Statistics. 2008. http://www.statistics.gov. uk (accessed 2 May 2008).
21. Dickman PW, Sloggett A, Hills M, et al. Regression models for relative survival. Stat Med 2004;23:51-64.
22. STATA statistical software College Station, TX: Stata Corporation; 2004.
23. Faivre-Finn C, Bouvier-Benhamiche AM, Phelip JM, et al. Colon cancer in France: evidence for improvement in management and survival. Gut 2002;51:60-4.
24. Sarfati D, Hill S, Blakely T, et al. The effect of comorbidity on the use of adjuvant chemotherapy and survival from colon cancer: a retrospective cohort study. BMC cancer 2009;9:115-25.
25. Gross CP, McAvay GJ, Guo Z, et al. The impact of chronic illnesses on the use and effectiveness of adjuvant chemotherapy for colon cancer. Cancer 2007;109:2410-19.
26. Janssen-Heijnen MLG, Maas HA, Houterman S, et al. Comorbidity in older surgical cancer patients: influence on patient care and outcome. Eur J Cancer 2007;43:2179-93.
27. Piccirillo JF, Tierney RM, Costas I, et al. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004;291:2441-47.
28. Gatta G, Capocaccia R, Sant M, et al. Understanding variations in survival for colorectal cancer in Europe: a EUROCARE high-resolution study. Gut 2000;47: 533-38.
29. Rieker RJ, Hammer E, Eisele R, et al. The impact of comorbidity on the overall survival and the cause of death in patients after colorectal cancer resection. Langenbecks Arch Surg 2002;387:72-6.
30. Garout M, Tilney HS, Tekkis PP, et al. Comparison of administrative data with the Association of Coloproctology of Great Britain and Ireland (ACPGBI) colorectal cancer database. Int J Colorectal Dis 2008;23:155-63.
31. Wood J, Hennell T, Jones A, et al. Where wealth means health: Illustrating inequalities in the North West. Liverpool: North West Public Health Observatory, 2006.
32. Nuttal M, van der Meulen J, Emberton M. Charlson scores based on ICD-10 administrative data were valid in assessing comorbidity in patients undergoing urological cancer surgery. J Clin Epidemiol 2006;59:265-73.
33. Klabunde CN, Legler JM, Warren JL, et al. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal and lung cancer patients. Ann Epidemiol 2007;17:584- 190.
34. Yorkshire and Humberside Public Health Observatory. Estimating diabetes diagnosis rates using QOF data. 2008. http://www.yhpho.org.uk (accessed 11 December 2008).
35. Halbert RJ, Isonaka S, George D, et al. Interpreting COPD prevalence estimates: What is the true burden of disease? Chest 2003;123:1684-92.
36. Jack RH, Davies EA, Møller H. Testis and prostate cancer incidence in ethnic groups in South East England. Int J Androl 2007;30:215-21.
37. Morris E, Quirke P, Thomas JD, et al. Unacceptable variation in abdominoperineal excision rates for rectal cancer: time to intervene? Gut 2008;12:1690-97.